This study evaluates the frequency and causes of dolutegravir (DTG) discontinuation along 5 years of follow-up, in both antiretroviral treatment (ART)-naive and experienced people living with HIV (PLWH). This is a prospective multi-center cohort study enrolling PLWH on DTG from July 2014 until November 2020. DTG-durability was investigated using the Kaplan–Meier survival curve. The Cox proportional-hazards model was used for estimating the hazard ratio (HR) of DTG discontinuation for any cause, and for adverse events (AEs). Nine hundred sixty-three PLWH were included, 25.3% were women and 28.0% were ART-naive. Discontinuations for any causes were 10.1 [95% confidence interval (95% CI) 8.9–11.5] per 100 person-years, similar in most regimens, with the apparent exception of tenofovir alafenamide/emtricitabine+DTG (p < 0.0001). In the multivariable Cox regression model, non-Caucasian ethnicity, age ≥50 years, and lower estimated glomerular filtration rate (eGFR) were associated with a higher probability of DTG interruption. The incidence rate of virological failure was 0.4 (95% CI 0.2–0.7) per 100 person-years, while the estimated discontinuation rate for AEs was 4.0 (3.2–4.9) per 100 person-years. Thirty-four DTG interruptions were due to grade ≥3 events (10 central nervous system, 6 hypersensitivity, 3 renal, 3 myalgia/asthenia, 3 abdominal pain, 2 gastrointestinal, and 7 other events). People with lower body mass index, age ≥50 years, and lower eGFR were at higher risk of AEs, while dual combinations were protective (HR 0.41 compared with abacavir/lamivudine/DTG, 95% CI 0.22–0.77). In this prospective observational study, we found high DTG durability and a low rate of virological failures. Dual therapies seemed protective toward AEs and might be considered, when feasible, a suitable option to minimize drug interactions and improve tolerability.
Get full access to this article
View all access options for this article.
References
1.
British HIV Association (BHIVA). BHIVA interim ART guidelines COVID-19 v2 07082020. Initiation of antiretroviral treatment (ART) during the coronavirus pandemic. 2020. Available at: https://www.bhiva.org/file/5f56057450cc3/BHIVA-interim-ART-guidelines-COVID-19.pdf (Last accessed June5, 2021).
2.
Di BiagioA, Cozzi-LepriA, PrinaporiR, et al.Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy. J Acquir Immune Defic Syndr, 2016; 71:263–271.
3.
DeeksSG, LewinSR, HavlirDV. The end of AIDS: HIV infection as a chronic disease. Lancet, 2013; 382:1525–1533.
4.
PanditNS, ChastainDB, PallottaAM, BadowskiME, HuesgenEC, MichienziSM. Simplifying ARV therapy in the setting of resistance. Curr Infect Dis Rep, 2019; 21:38.
5.
European AIDS Clinical Society (EACS) Guidelines Version 10.0. 2020. Available at: https://www.eacsociety.org/media/guidelines-10.1_30032021_1.pdf (Last accessed June5, 2021).
6.
DHHS Panel on Antiretroviral Guidelines for Adults andAdolescents. A Working Group of the Office of AIDSResearch, Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents withHIV.2021. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf (Last accessed June5, 2021).
7.
de Oliveira CostaJ, SchafferAL, MedlandNA, et al.Adherence to antiretroviral regimens in Australia: A nationwide cohort study. AIDS Patient Care STDS, 2020; 34:81–91.
8.
LaurenceJ, ElhadadS, AhamedJ. HIV-associated cardiovascular disease: Importance of platelet activation and cardiac fibrosis in the setting of specific antiretroviral therapies. Open Heart, 2018; 5:e000823.
9.
RossettiB, BaldinG, SterrantinoG, et al.Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: Results from a multicenter cohort study. Antiviral Research, 2019; 169:104552.
10.
BonfantiP, De VitoA, RicciE, et al.Bone safety of dolutegravir-containing regimens in people living with HIV: Results from a real-world cohort. Infect Drug Resist, 2020; 13:2291–2300.
11.
CicculloA, D'avinoA, LassandroAP, et al.Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: Preliminary results from clinical practice. Infez Med, 2018; 26:336–340.
12.
BagellaP, SquillaceN, RicciE, et al.Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: Data from the SCOLTA project. Infect Drug Resist, 2019; 12:1385–1391.
13.
TrottierB, LakeJE, LogueK, et al.Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): A 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther, 2017; 22:295–305.
14.
GatellJM, AssoumouL, MoyleG, et al.Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS, 2017; 31:2503–2514.
15.
TaramassoL, TatarelliP, RicciE, et al.Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA). BMC Infect Dis, 2018; 18:357.
16.
LlibreJM, PulidoF, GarcíaF, García DeltoroM, BlancoJL, DelgadoR. Genetic barrier to resistance for dolutegravir. AIDS Rev, 2015; 17:56–64.
17.
ClotetB, FeinbergJ, Van LunzenJ, et al.Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet, 2014; 383:2222–2231.
18.
CahnP, MaderoJS, ArribasJR, et al.Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, 2019; 393:143–155.
19.
WalmsleySL, AntelaA, ClumeckN, et al.Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med, 2013; 369:1807–1818.
20.
RaffiF, JaegerH, Quiros-RoldanE, et al.Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis, 2013; 13:927–935.
21.
BaldinG, CicculloA, RusconiS, et al.Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents, 2019; 54:728–734.
22.
De VitoA, CaruanaG, ClarkF, et al.Efficacy, safety and tolerability of dolutegravir-based combination antiretroviral therapy in clinical practice in HIV-infected patients: Results from a multicenter study. Infect Dis Trop Med, 2019; 5:e565.
23.
NasreddineR, FlorenceE, VandercamB, et al.Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients. AIDS, 2020; 34:1151–1159.
24.
de BoerMGJ, van den BerkGEL, van HoltenN, et al.Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS, 2016; 30:2831–2834.
25.
Povar-EcheverríaM, Comet-BernadM, Gasso-SánchezA, et al.Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice [in English, Spanish]. Enferm Infecc Microbiol Clin, 2020; 39:78–82.
26.
BonfantiP, MadedduG, GulminettiR, et al.Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS, 2017; 31:455–457.
27.
TaramassoL, BonfantiP, RicciE, et al.Factors associated with weight gain in people treated with dolutegravir. Open Forum Infect Dis, 2020; 7:0faa195.
28.
TaramassoL, RicciE, MenzaghiB, et al.Weight gain: A possible side effect of all antiretrovirals. Open Forum Infect Dis, 2017; 4:1–3.
29.
BourgiK, JenkinsCA, RebeiroPF, et al.Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc, 2020; 23:e25484.
30.
BonfantiP, MartinelliC, RicciE, et al.An Italian approach to postmarketing monitoring: Preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr, 2005; 39:317–320.
31.
DAIDS. Division of Aids Table for Grading the Severity of Adult and Pediatric Adverse Events Division of Aids Table for Grading the Severity of Adult and Pediatric Adverse Events. National Institute of Allergy and Infectious Diseases, 2017:1–35. Available at: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf (Last accessed June5, 2021).
32.
MadedduG, De SocioGVL, RicciE, et al.Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents, 2015; 45:289–294.
33.
SaracinoA, ZaccarelliM, LorenziniP, et al.Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. BMC Public Health, 2018; 18:870.
34.
MondiA, Cozzi-LepriA, TavelliA, et al.Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: Data from the Icona cohort. J Int AIDS Soc, 2019; 22:e25227.
35.
HoffmannC, WelzT, SabranskiM, et al.Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med, 2017; 18:56–63.
36.
StellbrinkH-J, ReynesJ, LazzarinA, et al.Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS, 2013; 27:1771–1778.
37.
CahnP, MaderoJS, ArribasJR, et al.Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr, 2020; 83:310–318.
38.
CahnP, PozniakAL, MingroneH, et al.Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet, 2013; 382:700–708.
39.
OrrellC, HaginsDP, BelonosovaE, et al.Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): Week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV, 2017; 4:e536–e546.
40.
van WykJ, AjanaF, BisshopF, et al.Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. Clin Infect Dis, 2020; 71:1920–1929.
41.
LlibreJM, HungC-C, BrinsonC, et al.Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet, 2018; 391:839–849.
42.
SharrarRG, DieckGS. Monitoring product safety in the postmarketing environment. Ther Adv Drug Saf, 2013; 4:211–219.
43.
ElliotER, WangX, SinghS, et al.Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis, 2019; 68:87–95.
44.
CalcagnoA, Moltó J, Borghetti A, et al. Older age is associated with higher dolutegravir exposure in plasma and cerebrospinal fluid of people living with HIV. Clin Pharmacokinet, 2021; 60:103–109.
45.
CourletP, StaderF, GuidiM, et al.Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. AIDS, 2020; 34:103–108.
46.
LetendreSL, MillsAM, TashimaKT, et al.ING116070: A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis, 2014; 59:1032–1037.
47.
BorghettiA, CalcagnoA, LombardiF, et al.SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother, 2019; 74:1035–1043.
48.
YaguraH, WatanabeD, KushidaH, et al.Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis, 2017; 17:622.
49.
WellerS, BorlandJ, ChenS, et al.Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol, 2014; 70:29–35.
50.
BarceloC, AouriM, CourletP, et al.Population pharmacokinetics of dolutegravir: Influence of drug-drug interactions in a real-life setting. J Antimicrob Chemother, 2019; 74:2690–2697.
51.
ParantF, MiailhesP, BrunelF, GagnieuM-C. Dolutegravir population pharmacokinetics in a real-life cohort of people living with HIV infection: A covariate analysis. Ther Drug Monit, 2019; 41:444–451.
52.
ZhangJ, HayesS, SadlerBM, et al.Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol, 2015; 80:502–514.
53.
ParantF, MiailhesP, BrunelF, GagnieuM-C. Dolutegravir-related neurological adverse events: A case report of successful management with therapeutic drug monitoring. Curr Drug Saf, 2018; 13:69–71.
54.
CastagnaA, MaggioloF, PencoG, et al.Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis, 2014; 210:354–362.
55.
CailholJ, RouyerC, AllouiC, JeantilsV. Dolutegravir and neuropsychiatric adverse events: A continuing debate. AIDS, 2017; 31:2023–2024.
56.
BorghettiA, BaldinG, CapettiA, et al.Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS, 2017; 31:457–459.
57.
CattaneoD, RizzardiniG, GervasoniC. Intolerance of dolutegravir-containing combination antiretroviral therapy: Not just a pharmacokinetic drug interaction. AIDS, 2017; 31:867–868.
58.
KongAM, PozenA, AnastosK, KelvinEA, NashD. Non-HIV comorbid conditions and polypharmacy among people living with HIV age 65 or older compared with HIV-negative individuals age 65 or older in the United States: A retrospective claims-based analysis. AIDS Patient Care STDS, 2019; 33:93–103.
59.
OkoliC, SchwenkA, RadfordM, et al.Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database. HIV Med, 2020; 21:471–480.
60.
LivioF, DeutschmannE, MoffaG, et al.Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. J Antimicrob Chemother, 2021; 76:758–764.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
